High Tide Inc. (NASDAQ: HITI) reported first‑quarter 2026 revenue of $178.3 million, a 25% year‑over‑year increase from $142.5 million in Q1 2025. The top‑line growth was driven by a 30% rise in Canadian retail sales, a 15% lift in medical‑cannabis revenue, and a $25 million contribution from its newly acquired Remexian Pharma GmbH in Germany.
The company’s revenue beat analyst expectations by roughly $51.5 million, surpassing the consensus estimate of $126.8 million. The beat was largely attributable to the expansion of the Canna Cabana retail network, which added 20 new stores and saw higher average transaction values, as well as the successful launch of Remexian’s product line in the German market, which added a new revenue stream and broadened High Tide’s international footprint.
Adjusted earnings per share were $0.01, matching the consensus estimate of $0.01. While some analysts had projected a slightly higher EPS of $0.02, the company’s cost‑control program and efficient inventory management helped it meet expectations. The EPS result reflects a combination of stable operating margins and disciplined expense management across both retail and medical segments.
Free cash flow turned positive at $2.9 million, compared with a $1.9 million loss a year earlier. The improvement was driven by higher operating cash generation from retail sales and a reduction in working‑capital requirements, offsetting the one‑time capital expenditures associated with the Remexian acquisition.
Gross margin for the quarter was 25%, consistent with the prior year and slightly below the 26% sequential level. The margin compression was mainly due to increased raw‑material costs in the medical segment, while the retail segment maintained a 28% gross margin thanks to pricing power and a higher mix of premium products.
CEO Raj Grover said, “With strong momentum in Canada, expanding international opportunities, and improving prospects in the United States, the future for High Tide is bright and increasingly global.” He added that the company’s discount‑club model continues to be the backbone of its success, citing record revenue and positive free cash flow as evidence of execution strength.
Following the release, the market reacted positively, with the stock rising 5.1% in extended trading. Analysts highlighted the record revenue, the 25% year‑over‑year growth, and the shift to positive free cash flow as key drivers of the favorable reaction.
Looking ahead, High Tide’s management expressed confidence in sustaining growth, citing continued expansion of its Canadian retail network and further penetration of the German medical market. The company’s ability to generate positive cash flow and maintain a solid gross margin positions it well to invest in new product lines and potential acquisitions, reinforcing its competitive advantage in the cannabis industry.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.